NASDAQ:BLRX

Biolinerx Stock Insider Trading

etoro logo Buy BLRX
*Your capital is at risk
$3.28
-0.110 (-3.24%)
At Close: Jun 03, 2026

BioLineRx Stock Insider Power

Based on the 68 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 52.54M and sold 0 BLRX shares in the last 68 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 68 transactions)
100.00
Buy 52.54M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Nov 19, 2026
Buy
Employee Stock Option (Right to Buy)
Zeevi Mali
Chief Financial Officer
C-Suite Officer 13 680 000
Value: $82.1K
Mar 18, 2026
Buy
Common Stock
J-Other
Yan Shaoyu
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, 0.1 NIS per share
Schwartz Aharon
Director
Director 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, 0.1 NIS per share
Serlin Philip A
Chief Executive Officer
CEO / President 0
Value: $0
Mar 18, 2026
Buy
Ordinary Shares, 0.1 NIS per share
Zeevi Mali
Chief Financial Officer
C-Suite Officer 0
Value: $0
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Molcho Avraham
Director
Director 2 055 000
Value: $106.9K
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Dar Rami
Director
Director 2 055 000
Value: $106.9K
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Hofstein Raphael
Director
Director 2 055 000
Value: $106.9K
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Panem Sandra
Director
Director 2 055 000
Value: $106.9K
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Schwartz Aharon
Director
Director 2 055 000
Value: $106.9K
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Cohen Gal Avraham
Director
Director 2 055 000
Value: $106.9K
Jan 01, 2025
Buy
Employee Stock Option (Right to Buy)
Bormann-kennedy Barbara-jean Anne
Director
Director 2 055 000
Value: $106.9K
Oct 03, 2024
Buy
Employee Stock Option (Right to Buy)
Molcho Avraham
Director
Director 360 000
Value: $30.6K
Oct 03, 2024
Buy
Employee Stock Option (Right to Buy)
Dar Rami
Director
Director 360 000
Value: $30.6K
Oct 03, 2024
Buy
Employee Stock Option (Right to Buy)
Hofstein Raphael
Director
Director 360 000
Value: $30.6K
Oct 03, 2024
Buy
Employee Stock Option (Right to Buy)
Panem Sandra
Director
Director 360 000
Value: $30.6K
Oct 03, 2024
Buy
Employee Stock Option (Right to Buy)
Schwartz Aharon
Director
Director 360 000
Value: $30.6K
Oct 03, 2024
Buy
Employee Stock Option (Right to Buy)
Bormann-kennedy Barbara-jean Anne
Director
Director 360 000
Value: $30.6K
Mar 21, 2024
Buy
Employee Stock Option (Right to Buy)
Serlin Philip A
Chief Executive Officer
CEO / President 4 495 200
Value: $202.3K
Mar 21, 2024
Buy
Employee Stock Option (Right to Buy)
Zeevi Mali
Chief Financial Officer
C-Suite Officer 1 078 800
Value: $48.5K
Oct 03, 2023
Buy
Employee Stock Option (Right to Buy)
Molcho Avraham
Director
Director 360 000
Value: $29.2K
Oct 03, 2023
Buy
Employee Stock Option (Right to Buy)
Dar Rami
Director
Director 360 000
Value: $29.2K
Oct 03, 2023
Buy
Employee Stock Option (Right to Buy)
Hofstein Raphael
Director
Director 360 000
Value: $29.2K
Oct 03, 2023
Buy
Employee Stock Option (Right to Buy)
Panem Sandra
Director
Director 360 000
Value: $29.2K
Oct 03, 2023
Buy
Employee Stock Option (Right to Buy)
Schwartz Aharon
Director
Director 360 000
Value: $29.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BIOLINERX LTD.
BioLineRx
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in pat...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE